Cargando…

The Core Cysteines, (C909) of Islet Antigen-2 and (C945) of Islet Antigen-2β, Are Crucial to Autoantibody Binding in Type 1 Diabetes

Cysteines are thought integral to conformational epitopes of islet antigen-2 (IA-2) autoantibodies (IA-2A), possibly through disulfide bond formation. We therefore investigated which cysteines are critical to IA-2A binding in patients with newly diagnosed type 1 diabetes. All 10 cysteines in the int...

Descripción completa

Detalles Bibliográficos
Autores principales: Elvers, Karen T., Geoghegan, Ivey, Shoemark, Debbie K., Lampasona, Vito, Bingley, Polly J., Williams, Alistair J.K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526053/
https://www.ncbi.nlm.nih.gov/pubmed/22966073
http://dx.doi.org/10.2337/db11-1590
_version_ 1782253498088292352
author Elvers, Karen T.
Geoghegan, Ivey
Shoemark, Debbie K.
Lampasona, Vito
Bingley, Polly J.
Williams, Alistair J.K.
author_facet Elvers, Karen T.
Geoghegan, Ivey
Shoemark, Debbie K.
Lampasona, Vito
Bingley, Polly J.
Williams, Alistair J.K.
author_sort Elvers, Karen T.
collection PubMed
description Cysteines are thought integral to conformational epitopes of islet antigen-2 (IA-2) autoantibodies (IA-2A), possibly through disulfide bond formation. We therefore investigated which cysteines are critical to IA-2A binding in patients with newly diagnosed type 1 diabetes. All 10 cysteines in the intracellular domain of IA-2 were modified to serine by site-directed mutagenesis, and the effects of these changes on autoantibody binding in comparison with wild-type control were investigated by radiobinding assay. Mutation of the protein tyrosine phosphatase (PTP) core cysteine (C909) in IA-2 caused large reductions in autoantibody binding. In contrast, little or no reduction in binding was seen following substitution of the other cysteines. Modification of the core cysteine (C945) in IA-2β also greatly reduced autoantibody binding. Lysine substitution of glutamate-836 in IA-2 or glutamate-872 in IA-2β resulted in modest reductions in binding and identified a second epitope region. Binding to IA-2 PTP and IA-2β PTP was almost abolished by mutation of both the core cysteine and these glutamates. The core cysteine is key to the major PTP conformational epitope, but disulfide bonding contributes little to IA-2A epitope integrity. In most patients, at disease onset, >90% of antibodies binding to the PTP domain of IA-2 recognize just two epitope regions.
format Online
Article
Text
id pubmed-3526053
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-35260532014-01-01 The Core Cysteines, (C909) of Islet Antigen-2 and (C945) of Islet Antigen-2β, Are Crucial to Autoantibody Binding in Type 1 Diabetes Elvers, Karen T. Geoghegan, Ivey Shoemark, Debbie K. Lampasona, Vito Bingley, Polly J. Williams, Alistair J.K. Diabetes Immunology and Transplantation Cysteines are thought integral to conformational epitopes of islet antigen-2 (IA-2) autoantibodies (IA-2A), possibly through disulfide bond formation. We therefore investigated which cysteines are critical to IA-2A binding in patients with newly diagnosed type 1 diabetes. All 10 cysteines in the intracellular domain of IA-2 were modified to serine by site-directed mutagenesis, and the effects of these changes on autoantibody binding in comparison with wild-type control were investigated by radiobinding assay. Mutation of the protein tyrosine phosphatase (PTP) core cysteine (C909) in IA-2 caused large reductions in autoantibody binding. In contrast, little or no reduction in binding was seen following substitution of the other cysteines. Modification of the core cysteine (C945) in IA-2β also greatly reduced autoantibody binding. Lysine substitution of glutamate-836 in IA-2 or glutamate-872 in IA-2β resulted in modest reductions in binding and identified a second epitope region. Binding to IA-2 PTP and IA-2β PTP was almost abolished by mutation of both the core cysteine and these glutamates. The core cysteine is key to the major PTP conformational epitope, but disulfide bonding contributes little to IA-2A epitope integrity. In most patients, at disease onset, >90% of antibodies binding to the PTP domain of IA-2 recognize just two epitope regions. American Diabetes Association 2013-01 2012-12-13 /pmc/articles/PMC3526053/ /pubmed/22966073 http://dx.doi.org/10.2337/db11-1590 Text en © 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Immunology and Transplantation
Elvers, Karen T.
Geoghegan, Ivey
Shoemark, Debbie K.
Lampasona, Vito
Bingley, Polly J.
Williams, Alistair J.K.
The Core Cysteines, (C909) of Islet Antigen-2 and (C945) of Islet Antigen-2β, Are Crucial to Autoantibody Binding in Type 1 Diabetes
title The Core Cysteines, (C909) of Islet Antigen-2 and (C945) of Islet Antigen-2β, Are Crucial to Autoantibody Binding in Type 1 Diabetes
title_full The Core Cysteines, (C909) of Islet Antigen-2 and (C945) of Islet Antigen-2β, Are Crucial to Autoantibody Binding in Type 1 Diabetes
title_fullStr The Core Cysteines, (C909) of Islet Antigen-2 and (C945) of Islet Antigen-2β, Are Crucial to Autoantibody Binding in Type 1 Diabetes
title_full_unstemmed The Core Cysteines, (C909) of Islet Antigen-2 and (C945) of Islet Antigen-2β, Are Crucial to Autoantibody Binding in Type 1 Diabetes
title_short The Core Cysteines, (C909) of Islet Antigen-2 and (C945) of Islet Antigen-2β, Are Crucial to Autoantibody Binding in Type 1 Diabetes
title_sort core cysteines, (c909) of islet antigen-2 and (c945) of islet antigen-2β, are crucial to autoantibody binding in type 1 diabetes
topic Immunology and Transplantation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526053/
https://www.ncbi.nlm.nih.gov/pubmed/22966073
http://dx.doi.org/10.2337/db11-1590
work_keys_str_mv AT elverskarent thecorecysteinesc909ofisletantigen2andc945ofisletantigen2barecrucialtoautoantibodybindingintype1diabetes
AT geogheganivey thecorecysteinesc909ofisletantigen2andc945ofisletantigen2barecrucialtoautoantibodybindingintype1diabetes
AT shoemarkdebbiek thecorecysteinesc909ofisletantigen2andc945ofisletantigen2barecrucialtoautoantibodybindingintype1diabetes
AT lampasonavito thecorecysteinesc909ofisletantigen2andc945ofisletantigen2barecrucialtoautoantibodybindingintype1diabetes
AT bingleypollyj thecorecysteinesc909ofisletantigen2andc945ofisletantigen2barecrucialtoautoantibodybindingintype1diabetes
AT williamsalistairjk thecorecysteinesc909ofisletantigen2andc945ofisletantigen2barecrucialtoautoantibodybindingintype1diabetes
AT elverskarent corecysteinesc909ofisletantigen2andc945ofisletantigen2barecrucialtoautoantibodybindingintype1diabetes
AT geogheganivey corecysteinesc909ofisletantigen2andc945ofisletantigen2barecrucialtoautoantibodybindingintype1diabetes
AT shoemarkdebbiek corecysteinesc909ofisletantigen2andc945ofisletantigen2barecrucialtoautoantibodybindingintype1diabetes
AT lampasonavito corecysteinesc909ofisletantigen2andc945ofisletantigen2barecrucialtoautoantibodybindingintype1diabetes
AT bingleypollyj corecysteinesc909ofisletantigen2andc945ofisletantigen2barecrucialtoautoantibodybindingintype1diabetes
AT williamsalistairjk corecysteinesc909ofisletantigen2andc945ofisletantigen2barecrucialtoautoantibodybindingintype1diabetes